<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="loss prevention strategies (eg, minimizing blood draws or treatment with" exact="tranexamic acid" post="if clinically permissible) should be maximized [10]. The use"/>
 <result pre="15, 2020, the US Food and Drug Administration (FDA) revoked" exact="chloroquine" post="and hydroxychloroquine's emergency use authorization in response to the"/>
 <result pre="and other potential serious side effects, the potential benefits of" exact="chloroquine" post="and hydroxychloroquine do not outweigh the risks of their"/>
 <result pre="potential serious side effects, the potential benefits of chloroquine and" exact="hydroxychloroquine" post="do not outweigh the risks of their use. The"/>
 <result pre="Agents that likely will not work, according to the literature" exact="Azithromycin" post="Tested in a French trial and found to reinforce"/>
 <result pre="French trial and found to reinforce the positive effect of" exact="hydroxychloroquine" post="on the COVID-19 viral load [41]. Used as a"/>
 <result pre="enhanced if used concurrently with full-dose azithromycin, chloroquine, or both." exact="Chloroquine" post="and hydroxychloroquine Best evidence thus far has failed to"/>
 <result pre="used concurrently with full-dose azithromycin, chloroquine, or both. Chloroquine and" exact="hydroxychloroquine" post="Best evidence thus far has failed to demonstrate benefit"/>
 <result pre="no benefit and association with higher mortality in patients receiving" exact="hydroxychloroquine" post="[43]. Other studies have shown no benefit and potential"/>
 <result pre="arrhythmias 44, 45, 46, 47. Concerns about increased toxicity with" exact="cyclosporine" post="and imatinib (used in chronic GVHD), such as myopathies."/>
 <result pre="45, 46, 47. Concerns about increased toxicity with cyclosporine and" exact="imatinib" post="(used in chronic GVHD), such as myopathies. Agents that"/>
 <result pre="Castleman's disease Use only in the context of clinical trials." exact="Ruxolitinib" post="Possible role in hemophagocytic lymphohistiocytosis due to COVID-19 (trials"/>
 <result pre="patients; thus, cautious use in clinical trials only is recommended." exact="Ibrutinib" post="Reported as perhaps beneficial for COVID-19 in a retrospective"/>
 <result pre="the reported study were already on ibrutinib. Caution against using" exact="ibrutinib" post="solely for COVID-19 infection in HCT recipients until trial"/>
 <result pre="on in ARDS due to COVID-19 Interactions with other drugs" exact="Voriconazole" post="and posaconazole No known role in COVID-19 Commonly used"/>
 <result pre="ARDS due to COVID-19 Interactions with other drugs Voriconazole and" exact="posaconazole" post="No known role in COVID-19 Commonly used in GVHD."/>
 <result pre="posaconazole No known role in COVID-19 Commonly used in GVHD." exact="Azithromycin" post="interaction with the CYP3A4 inducers. CAR T cells (cryopreserved"/>
 <result pre="COVID-2019 infectionClin Chem Lab Med5820201131113432119647 17Principi N, Esposito S.Chloroquine or" exact="hydroxychloroquine" post="for prophylaxis of COVID-19 [e-pub ahead of print]. Lancet"/>
 <result pre="2020. 18CortegianiAIngogliaGIppolitoMGiarratanoAEinavS.A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J Crit Care57202027928332173110 19ZhangLZhuFXieLClinical characteristics"/>
 <result pre="therapy in severe COVID-19 patients: a pilot studymedRxiv202003.16.20036145 41GautretPLagierJCParolaPHydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
 <result pre="an open-label non-randomized clinical trialInt J Antimicrob Agents562020105949 42ChenZHuJZhangZEfficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
 <result pre="with COVID-19: results of a randomized clinical trialmedRxiv202003.22.20040758 43MagagnoliJNarendranSPereiraFOutcomes of" exact="hydroxychloroquine" post="usage in United States veterans hospitalized with COVID-19medRxiv202004.16.20065920 44GelerisJSunYPlattJObservational"/>
 <result pre="in United States veterans hospitalized with COVID-19medRxiv202004.16.20065920 44GelerisJSunYPlattJObservational study of" exact="hydroxychloroquine" post="in hospitalized patients with Covid-19N Engl J Med38220202411241832379955 45RosenbergESDufortEMUdoTAssociation"/>
 <result pre="patients with Covid-19N Engl J Med38220202411241832379955 45RosenbergESDufortEMUdoTAssociation of treatment with" exact="hydroxychloroquine" post="or azithromycin with in-hospital mortality in patients with COVID-19"/>
 <result pre="Covid-19N Engl J Med38220202411241832379955 45RosenbergESDufortEMUdoTAssociation of treatment with hydroxychloroquine or" exact="azithromycin" post="with in-hospital mortality in patients with COVID-19 in New"/>
 <result pre="trialBMJ3692020m184932409561 47Mehra MR, Desai SS, Ruschitzka F, Patel AN. RETRACTED:" exact="Hydroxychloroquine" post="or chloroquine with or without a macrolide for treatment"/>
 <result pre="MR, Desai SS, Ruschitzka F, Patel AN. RETRACTED: Hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
</results>
